ilmscore | Prediction Details
"the company's earnings growth would be broadly low single digit to mid single digit, such that earnings growth would be accounting for revenue losses... India probably would continue to deliver that high single digit to low double digit growth but the US will actually drag the earnings down"
By Groww | April 24, 2025 | Pending
From video
Sensex, Nifty rally pauses; FMCG & realty stocks fall | Tariff-proofing your pharma portfolio 00:25:25 - 00:25:48
Interpreted Prediction
Indian pharma companies with high US exposure are predicted to experience low single-digit to mid-single-digit earnings growth over the next 3-5 years, as US market drag offsets high single-digit to low double-digit growth in India.

Prediction Details

Topic
Indian Pharma Earnings Growth

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.